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Abstract 
 
Objective: Firstly to test the hypothesis that, amongst working patients with axSpA, those who report 
issues with reduced productivity at work (presenteeism) are at higher risk of work absence 
(absenteeism), and patients who report absenteeism are at higher risk of subsequently of leaving the 
workforce. Secondly to identify characteristics of workers at high risk of poor work outcome.  
 
Methods: The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis has 
recruited patients meeting ASAS criteria for axSpA from eighty-three centres. Data collection involves 
clinical and patient reported measures at recruitment and annually thereafter, including the Work 
Productivity and Activity Impairment scale. Generalised Estimating Equations were used to identify 
factors associated with   poor work outcomes. 
 
Results: Of the 1188 participants in this analysis who were working at recruitment, 79% reported some 
presenteeism and 19% some absenteeism in the past week due to their axSpA. Leaving employment 
was most strongly associated with  previous absenteeism  (Risk Ratio 1.02 per % increase in 
absenteeism, 95% CI 1.01, 1.03) which itself was most strongly associated with previous presenteeism, 
a labour intensive job and peripheral joint involvement. High disease activity, fatigue, a labour 
intensive job and poorer physical function were all independently associated with future 
presenteeism.  
 
Conclusion:  Clinical and patient reported factors along with aspects of work are associated with an 
increased risk of axSpA patients having a poor outcome in relation to work. This study has identified 
modifiable factors as targets, facilitating patients with axSpA to remain productive in work. 
 
 
  
3 | P a g e  
 
Introduction 
 
Axial spondyloarthritis has been demonstrated to affect the work of patients. The impact includes, at 
its most extreme, the necessity to stop working or to change jobs to one more suited to limitations 
imposed on the patient by their condition. Another important impact is the effect which having axSpA 
has on being able to perform one’s job (presenteeism) (1).  In a study of 301 patients with axSpA in a 
single centre in the United Kingdom which used the Work Productivity and Activity Impairment scale 
to measure work impact, mean levels of absenteeism due to axSpA was 5% but 22% for presenteeism 
(2), while similar data (absenteeism 9%, presenteeism 33%) was provided from an analysis of 105 
patients in the SPondyloArthritis Caught Early (SPACE) study involving four centres in the Netherlands, 
Norway and Italy (3). 
 
Patients consider that work should be a priority for research studies. The National Ankylosing 
Spondylitis Society (NASS), the patient organisation in the United Kingdom which represents and 
supports people with ankylosing spondylitis (AS), carried out a formal project in 2013 to understand 
the key priorities for patients in terms of research. All members were invited to respond to the 
question ‘What kinds of issues need to be understood better to make living with and managing AS 
easier” and responses from 150 members fed in to a subsequent priority setting exercise using a World 
Café format (4) involving rheumatologists, clinicians and allied health professionals. Amongst 
“lifestyle” factors, the top research priority identified was to “Understand the impact of AS on 
employment and how people maintain employment and develop their careers while managing their 
AS” (https://nass.co.uk/nass/en/research).  
 
It has been noted that “Even more than today, work will become as much a social act as an economic 
one. It will help define us as individuals, provide social networks, support, community and …. 
connection to a wider purpose” (5). This emphasises the wider importance of enabling patients with 
axSpa and other chronic conditions, to remain in the workplace. A key issue in doing so is to 
understand the pathway leading to a poor work outcome, allowing the identification of a group of 
“high risk” patients.  We propose, firstly, to test the hypothesis that working patients with axSpA who 
report issues with work productivity are at higher risk of work absence, and patients who report work 
absence are at higher risk of subsequently of leaving the workforce. If the model is supported, we will 
identify characteristics of patients at risk of poor work outcome.  
 
Materials and Methods 
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The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) is a 
prospective cohort study, involving 83 centres throughout Great Britain, recruiting patients meeting 
ASAS criteria for axial spondyloarthropathitis (axSpA) (6) and who were naïve to biologic therapy. 
Recruitment took place December 2012-December 2017, initially for patients meeting the ASAS 
imaging criteria for axSpA. Patients who met only the ASAS clinical criteria were subsequently eligible 
to be recruited from November 2014.  There are two sub-cohorts: those about to commence a biologic 
agent (biologic cohort) and those continuing on other therapy (non-biologic cohort). Eligible therapies 
were adalimumab, etanercept and certolizumab pegol. The full study protocol has been published 
previously (7).Participants were required to be aged at least 16 years and be naïve to biologic therapy 
at the time of recruitment. All participants gave informed consent. The biologic cohort was followed 
up at 3 months and 6 months, and both cohorts were followed-up at 12 months and yearly thereafter 
up to a maximum of 5 years.  If a patient in the non-biologic cohort commenced biologic therapy they 
switched cohort and began a new follow-up schedule.    At each follow-up, in addition to clinical data 
obtained during rheumatology appointments, patient reported questionnaires were completed. 
 
The primary outcome of interest for the current analysis was poor work outcome, as assessed by the 
Work Productivity and Activity Impairment Specific Health Problem v2.0 (WPAI:SHP) scale (8).  This 
instrument determines work status and then, amongst those working, evaluates the impact of disease 
on work, and other daily activities, over the previous 7 days.  The outcomes generated include a 
measure of the proportion of work-time missed (absenteeism), impairment whilst at work 
(presenteeism), overall work impairment (combination of absenteeism and presenteeism) and 
proportion of impairment in other activities.  This instrument has been validated for use within 
ankylosing spondylitis patients (9). In relation to their job, respondents were also asked whether it 
was mainly desk-based/sedentary or physical/labour intensive. 
 
Measures at recruitment (baseline) and at each follow-up time point, used in the current analysis as 
explanatory variables, include clinical data: the use of biologic therapy (yes/no), presence of extra-
spinal manifestations (history of uveitis, psoriasis, inflammatory bowel disease (IBD), peripheral joint 
involvement and dactylitis) and the Bath Ankylosing Spondylitis Metrology Index (BASMI: scored 0 
(least) - 10 (most) severe) (10). Patient reported measures of health included the Bath Ankylosing 
Spondylitis indices for disease activity (BASDAI), function (BASFI) and global health (BAS-G) (all scored 
from 0 (least) – 10 (most) severe) (11-13).  Quality of life was evaluated via the Ankylosing Spondylitis 
Quality of Life index (ASQoL) (scored 0 (good) to 18 (poor)) (14), overall health by the European Quality 
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of Life – Visual Analogue Scale (EQ-VAS) (scored 0 (worst imaginable health) to 100 (best imaginable)) 
(15) and mental health using the Hospital Anxiety and Depression Scale (HADs) (grouped into none, 
borderline and clinical through standard cut-offs) (16).  Spinal pain was assessed using a 10cm visual 
analogue scale, fatigue through the Chalder fatigue scale (scored 0 (best) – 11 (worst)) (17), and sleep 
disturbance by the Jenkins Sleep Evaluation Questionnaire (JSEQ) (scored 0 (no sleep problems) to 20 
(poor sleep)) (18).  
 
A measure of socio-economic status, the Index of Multiple Deprivation (IMD), was derived from the 
residence postcode of participants; categorised into quintiles (0 least deprived to 4 most deprived) 
with reference to their country of residence (19, 20).  
 
The BSRBR-AS received ethical approval from the National Research Ethics Service (NRES) Committee 
North East – County Durham and Tees Valley (REC ref 11/NE/0374).   
 
Statistical Analysis: 
 
For the purpose of the current study, data collected at baseline and all follow-ups were utilised and 
the analysis uses the June 2017 version of the study database.  
 
Differences in the characteristics of those working and not working at baseline were assessed using 
simple descriptive statistics, including initial absenteeism, presenteeism and overall work impairment 
scores.  The baseline likelihood of working was further assessed using logistic regression models, 
adjusted for age, gender and deprivation.   
 
To test the initial hypothesis, three separate analyses were conducted to determine the factors 
associated with: a) leaving work, b) absenteeism and c) presenteeism, at 12 month follow-up intervals. 
Participants were categorised as having left work if they were not working at a follow-up assessment 
but had been working 12 months prior, and they were of normal working age (females <60years and 
males <65 years).  Factors associated with  work withdrawal were explored using generalised 
estimating equation (GEE) models (21).  GEE takes into account within-subject correlations, thus 
allowing the analysis of multiple observations from the same individual across multiple time-points. 
Thus baseline information was related to work outcome at 12 months, 12 month information was 
related to  work outcome at 24 months and so on.   The log link function was used (fitting a Poisson 
model) as appropriate, with an independent correlation matrix, including a robust variance estimator 
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(22).   All models were adjusted for age, gender and deprivation, and presented as risk ratios or 
coefficents with 95% confidence intervals. 
 
Factors related to  a) leaving work,  b) absenteeism and c) presenteeism, were assessed initially by 
GEE regression models as outlined above. Those factors reaching a significance threshold of p≤0.20 
were offered to a forward stepwise regression process (linear GEE or Poisson GEE as appropriate) in 
order to determine which group of factors produced the best fitting models for the outcomes leaving 
work, presenteeism and absenteeism.  Factors entered the model at p≤0.10 and exited at p≥0.15 with 
adjustment for age, gender, deprivation and relevant baseline measures (absenteeism or 
presenteeism as applicable). 
 
All analysis was conducted using STATA (StataCorp LP version 15.0). 
 
Results 
 
At baseline, 1,921 participants returned a questionnaire and provided information on work status.  Of 
these, 62% (n=1188) reported they were currently in paid employment and these represent the study 
population for the current analysis: 65% were male, with a median age of 44 years (Inter-quartile 
range (IQR) 35, 52 years), 55% worked in a sedentary job, 83% of those tested were HLA-B27 +ve and 
the median age of referral to a rheumatologist with symptoms was 33 years (IQR 26, 42 years).  The 
likelihood of working decreased (after adjustment for age, gender and deprivation) with higher 
disease activity (OR 0.74 per unit increase in BASDAI, (95% CI 0.70, 0.79)), poorer physical function 
(BASFI 0.70/unit increase (0.66, 0.73)), poorer spinal mobility (BASMI 0.69/unit increase (0.64, 0.75)) 
and worse quality of life (ASQoL 0.84/unit increase (0.81, 0.86)) (Table 1).  A higher proportion of those 
not working fulfilled the modified New York criteria for Ankylosing Spondylitis, compared to those 
working (15% vs. 7%).  Amongst working participants, 79% reported some presenteeism, due to their 
axSpa, during the past week (median 30% IQR (10, 50%)), while 19% reported some absenteeism (0% 
(0, 0%). 
 
Factors associated with leaving work during follow-up 
 
The 1,188 participants working at baseline provided a total of 962 annual periods of observation (i.e. 
12 month periods where both exposure and outcome information was available) when they were still 
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of normal working age (based on gender). In total 52 persons reported leaving work during follow-up 
while still of working age. 
 
In the GEE analysis, utilizing all follow-up time points and adjusted for age, gender and deprivation, 
absenteeism was the only significant factor related to leaving work 12 months later (Risk Ratio 1.02 
per % increase in absenteeism, 95% confidence interval 1.01, 1.03) (Table 2).  There were no 
statistically significant or important differences between those who remained and did not remain in 
work in terms of whether they were receiving biologic therapy, anxiety or depression, Bath indices, 
quality of life, activity impairment, spinal pain, fatigue or sleep disturbance.  Neither were there 
significant differences in presenteeism or whether they worked in a manual or sedentary job.  A 
further stepwise model was therefore not necessary.  The relationship with peripheral joint 
involvement or the presence of dactylitis with work withdrawal were not assessed, due to the low 
number of such persons (1 and 0 persons respectively). 
 
 
Factors associated with future absenteeism 
 
Utilising all follow-up time points, adjusted for age, gender and deprivation, the GEE models indicated 
that several factors were significantly associated with absenteeism 12 months later (Table 3).  These 
included work factors (presenteeism: 0.14% average increase in absenteeism at follow-up for every % 
increase in presenteeism at baseline, (95% CI 0.07, 0.2), a labour intensive job (2.7 (0.4, 4.9)), Bath 
indices (BASDAI 1.2 (0.7, 1.8), BASFI 0.9 (0.4, 1.4), BAS-G 1.1 (0.6, 1.6)), quality of life (ASQoL 0.5 (0.3, 
0.8)), activity impairment (0.13 (0.08, 0.2)), spinal pain (1.01 (0.5, 1.5)), fatigue (Chalder 0.4 (0.02, 0.8)) 
and sleep disturbance (JSEQ 0.4 (0.2, 0.6)).  Although eligible for the stepwise model, both activity 
impairment and presenteeism were highly correlated (correlation 0.8).  During the stepwise process, 
both factors fought for entry and a model solution could not be reached.  As it was not possible to 
offer both factors to the model, presenteeism was chosen as it showed the strongest relationship to 
absenteeism during univariate analysis (Coef 0.14 vs. 0.13).  Of the eligible factors offered to the 
stepwise model (p≤0.20, with adjustment for age, gender, deprivation and baseline absenteeism), the 
only ones which entered the linear regression model (in order) were presenteeism (0.1 (0.04, 0.2)), a 
labour intensive job (2.3 (-0.4, 5.0) and peripheral joint involvement (4.3 (-0.4, 5.0)) (Appendix Table 
a).  
 
Factors associated with future presenteeism: 
8 | P a g e  
 
 
Utilising all follow-up time points, adjusted for age, gender and deprivation, the GEE models indicated 
that several factors were significantly associated with presenteeism 12 months later (Table 4). 
Clinical/borderline anxiety and depression (coefficient 10.7 (95% CI 7.2, 14.2) and 10.0 (5.9, 14.1) 
respectively), higher disease activity, poorer physical function, poorer spinal mobility and global 
disease status were associated with greater presenteeism (BASDAI: 4.2 (3.6, 4.9), BASFI: 3.7 (3.0, 4.3), 
BASMI: 1.4 (0.3, 2.5), BAS-G: 3.4 (2.8, 4.0)), as was poorer quality of life (ASQoL: 2.0 (1.7, 2.3), EQ_VAS: 
-0.3 (-0.4, -0.2)), activity impairment (0.4 (0.3, 0.43)), worse spinal pain (2.8 (2.2, 3.4)), fatigue 
(Chalder: 2.3 (1.8, 2.8)) and sleep disturbance (JSEQ: 1.1 (0.8, 1.4)).  Lastly, commencing biologic 
therapy (6.6 (2.1, 11.1)), peripheral joint involvement (6.2 (1.9, 10.6)), a labour-intensive job (7.3 (3.8, 
10.7) and greater absenteeism (0.2 (0.02, 0.3)) were also associated with subsequent presenteeism. 
Of the eligible factors offered to the stepwise linear regression model (p≤0.20), the only independent 
factors related to presenteeism at follow-up, after adjustment for age, gender, deprivation and 
baseline presenteeism, were (in order of entry): high disease activity (BASDAI coefficient 0.76 (95% CI 
-0.2, 1.8)), fatigue (Chalder 0.7 (0.1, 1.2)), a labour intensive job (3.4 (0.6, 6.1)) and poorer physical 
function (BASFI 0.9 (-0.03, 1.8)) (Appendix Table b). There were no interactions in this final model 
which were statistically significant.  
 
 
Discussion 
 
This large national prospective cohort study of patients with axSpA has demonstrated that persons of 
working age who are not in employment have worse disease activity and function and overall poorer 
quality of life.  One out of five patients reported absenteeism in the past week while four out of five 
reported an impact on their ability to undertake tasks while at work. Our proposed pathway to leaving 
work was supported. It was associated with prior absenteeism, which itself was associated with prior 
presenteeism and having a labour intensive job. Disease activity, fatigue, poor function and a labour 
intensive job were the factors most strongly related to   future presenteeism.  
  
The strengths of this study include that it is amongst the largest to examine the impact of work on 
axSpA and specifically to identify markers of poor work outcome. It has used a validated scale (the 
WPAI:SHP) to assess work impact. However the scale only measures the impact of work over the past 
seven days and in a disease with a fluctuating course and disease “flares”, such a short period is 
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unlikely to adequately estimate work impact at an individual level. The resulting misclassification of 
work impact (and assuming that this is random)  would make it more difficult to identify factors 
associated with poor work outcome. Developing scales more suited for use in longitudinal studies to 
capture (changes in) work impact in conditions like axSpA, should be a priority. The study has recruited 
over more than 80 centres, some are specialist centres for axSpA but most are not. Almost all patients 
meeting ASAS criteria were eligible to be recruited (only those who had previously started biologic 
therapy were not eligible) and in terms of the recruited population on biologics we have shown that 
they are similar to the axSpA patient population recruited to trials of biologics (23). Despite the large 
study population, the number of persons developing the extreme end of a poor work outcome (i.e. 
leaving employment) is relatively low and therefore this study, as all studies in this area, has limited 
power in developing statistical models for this outcome. We have  conducted the statistical analysis 
over one year periods, examining different outcomes and therefore we are studying different patients 
in relation to each of the outcomes analysed rather than following patients longitudinally through 
presenteeism, absenteeism and job loss. The latter, more methodologically robust, approach would 
require a long-term and very large study of employed axSpA patients which is unlikely to be feasible. 
 
There is relatively little data on the effect of specific aspects of work and its influence on axSpA or 
indeed the effect of axSpA on the ability to undertake certain jobs. The prospective study DEvenir des 
Spondyloarthrites Indifférenciées Récentes (DESIR) examined trajectories of disease and factors 
associated with these. They noted that “white collar work” was associated with the trajectory 
“persistent inactive” disease (24). Ramiro et al (25) reported in a longitudinal analysis of 136 patients 
that the relationship between disease activity and radiographic progression was significantly and 
independently modified by job type. In 'blue-collar' workers versus 'white-collar' workers, every 
additional unit of ASDAS resulted in an increase of 1.2 v. 0.2 in the modified Stoke Ankylosing 
Spondylitis Spine Score (mSASSS) units/2-years. These results could be interpreted as supporting the 
hypothesis that physically demanding jobs increase levels of inflammation. However they may also 
reflect confounding. Job category (blue collar v. white collar) is very closely linked to income and socio-
economic status (SES), and also smoking status. The latter specifically has been linked to disease 
activity and radiographic progression (26).  
 
In a study of 72 employed patients recruited in one centre of the Netherlands, 12% had sick leave over 
a period of 2 weeks and 53% experienced an adverse influence of ankylosing spondylitis (AS) on work 
productivity while at work, emphasising, as has been found in this current much larger study, the 
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importance of considering presenteeism when assessing work impact in axSpA (27). The relationship 
between high disease activity and work impact has previously been reported in cross-sectional studies. 
For example, a small study of 51 Italian patients recruited to the SPACE study showed an association 
with absenteeism, presenteeism and overall work productivity, relationships also evident with poor 
function (28). Bakland et al (29) recruited 360 patients, registered with AS in a single hospital in 
Norway, to a cross-sectional study. Work disability was related to current poor function (BASFI) and 
mobility (BASMI), co-morbidities, as well as older age, female sex and lower levels of education. All 
these data are cross-sectional, and while giving important insights do not allow us to understand the 
pathways to work disability and cannot disentangle factors leading to work disability from 
consequences of work disability. For example the observation that patients with rheumatoid arthritis 
who remain in employment have better health–related quality of life (30) could be interpreted as 
employment having positive effects on quality of life or that those with higher quality of life and lower 
disease severity are more able to stay in employment.  
 
A longitudinal analysis of 720 patients with axSpA in Sweden, found that poor quality of life, worse 
disease activity, decreased physical function, lower self-efficacy, higher scores of anxiety, depression, 
smoking and low education were related to work disability two and a half years later (31). An 
important longitudinal analysis of 105 participants in the previously noted SPACE study demonstrated 
that improvements in disease activity were related to improvement in work productivity. Specifically 
a decrease in Ankylosing Spondylitis Disease Activity Score (ASDAS) of one unit was associated with a 
5% and 17% improvement in absenteeism and presenteeism respectively (3). We have previously 
shown within the BSRBR-AS, using propensity score matching, that biologic therapy is associated with 
a significantly greater improvement in presenteeism 12 months later, in comparison to patients 
continuing on other therapies (‐14.3%; 95% CI ‐24.7%, ‐4.0%) (32). Similarly in a cohort of axSpA 
patients in Sweden starting anti-TNFi therapy, their number of sick days decreased from 3 times to 2 
times that of the general population over the subsequent 2 years (33). Taken together with the current 
results, this body of evidence is suggestive of a direct relationship between disease activity and 
presenteeism.   
 
The current analysis shows an important association between  high levels of fatigue and presenteeism 
and this has been noted in some previous studies.  In the cross-sectional study of Espahbodi et al (2) 
high levels of fatigue in patients with axSpA were associated with work productively loss and 
absenteeism. In rheumatoid arthritis (RA) where fatigue has been demonstrated as an important 
influence on poor quality of life and employment (34, 35), improvement in physical function and relief 
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from fatigue and pain have been associated with increased productivity at work amongst patients 
treated with certolizumab pegol (36). However drug therapy (including biologics) only modestly 
improves fatigue in RA (37). Results from preliminary studies of non-pharmacological management 
(cognitive behaviour therapy) in RA give cause for optimism (Dures et al (38)) and randomised 
controlled trials are currently underway to assess the effectiveness of physical activity or cognitive 
behaviour therapy in improving fatigue both in RA and across inflammatory rheumatic disorders ((39) 
http://www.arthritisresearchuk.org/research/grant-tracker-items/2016/lessening-the-impact-of-
fatigue-therapies-for-inflammatory-rheumatic-diseases-lift.aspx). Amongst workers, such approaches 
are unlikely to achieve optimal results unless they are at least partly focussed on work place issues 
(40).  
 
In conclusion, this analysis of a national disease register has shown that high disease activity, fatigue, 
poor function and undertaking a physically demanding job, are  associated with patients reporting 
presenteeism at work. Presenteeism and undertaking a physically demanding job increases the risk of 
absenteeism which is then associated with leaving work altogether. These results characterise workers 
at high risk of a poor outcome but also identify targets which could improve such outcomes. While 
biologic therapy, targeting disease activity, has been shown to effect modest improvements in fatigue, 
providing non-pharmacological therapies which includes specific focus on the workplace is likely to be 
necessary to observe the improvements which patients seek.  
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Table 1:  Baseline characteristics of the BSRBR-AS population 
 Working (n=1188) Not working (n=733) 
**Age (median, IQR) 43.7 (34.6, 52.3) 62.2 (48.1, 68.3) 
**Age at rheumatology referral (median, IQR) 33 (26, 42) 41 (29, 52) 
*Gender (N., %) Male: 797 (65%) Male: 529 (72%) 
**Classification criteria (N., %) – ASAS clinical 635 (53%) 237 (32%) 
ASAS imaging 475 (40%) 383 (52%) 
Modified New York 78 (7%) 113 (15%) 
**HLA B27 status (N., %) – Positive 684 (83%) 337 (75%) 
Negative 145 (17%) 115 (25%) 
Job Type (N., %) - Sedentary 715 (55%) - 
Labour intensive 592 (45%) - 
Absenteeism (%) (median, IQR) 0% (0, 0%) - 
Presenteeism (%)  (median, IQR) 30% (10, 50%) - 
Overall Work impairment (%)  (median, IQR) 30% (10, 53%) - 
**Activity impairment (%) (median, IQR) 30% (10, 60%) 60% (30, 80%) 
 
Logistic Regression 
(adjusted for age, gender and deprivation) 
Likelihood of working Odds Ratio 95% Confidence Interval 
**BASDAI (scored: 0 best -10 worst) 0.74 0.70, 0.79 
**BASFI (scored: 0 best -10 worst) 0.70 0.66, 0.73 
**BASMI (scored: 0 best -10 worst) 0.69 0.64, 0.75 
**ASQoL (scored: 0 best -18 poorest) 0.84 0.81, 0.86 
* statistically significant difference between work and not working of p<0.05 
** statistically significant difference between work and not working of p<0.01 
BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, BASFI – Bath Ankylosing Spondylitis Functional Index, BASMI 
– Bath Ankylosing Spondylitis Metrology Index, ASQoL – Ankylosing Spondylitis Quality of Life questionnaire,  
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Table 2:  Factors associated with no longer working 12 months later 
 
GEE Poisson Regression  
(adj. for age, gender and deprivation) 
Baseline factors  Risk Ratio 95% Confidence Interval 
Work: Job Type (labour intensive vs. sedentary) 1.4 (0.8, 2.5) 
 Absenteeism (%) 1.02 (1.01, 1.03) 
 Presenteeism (%) 1.0003 (0.99, 1.01) 
Clinical: Commencing biologic (yes vs. no) 1.01 (0.5, 2.3) 
 Uveitis (yes vs. no) 0.5 (0.2, 1.3) 
 Psoriasis (yes vs. no) 1.2 (0.5, 3.1) 
 Inflammatory Bowel Disease (yes vs. no) 0.99 (0.3, 2.8) 
 Dactylitis (yes vs. no) low number of observations  
 Peripheral Joint Involvement (yes vs. no) low number of observations 
 BASDAI (score 0-10) 0.96 (0.8, 1.1) 
 BASFI (score 0-10) 1.02 (0.9, 1.1) 
 BASMI (score 0-10) 1.1 (0.9, 1.5) 
 BAS-G (score 0-10) 1.1 (0.9, 1.2) 
Patient: ASQoL (score 0-18) 1.03 (0.97, 1.1) 
 EQ-VAS (score 0-100) 0.99 (0.98, 1.01) 
 Activity Impairment (%) 1.01 (0.99, 1.02) 
 Spinal Pain (score 0-10) 1.001 (0.9, 1.1) 
 Chalder fatigue (score 0-11) 0.97 (0.9, 1.1) 
 Sleep Disturbance (score 0-20) 0.99 (0.95, 1.04) 
 HADS Anxiety (clinical/border vs. none) 1.04 (0.6, 1.8) 
 HADS Depression (clinical/border vs. none) 1.5 (0.8, 2.7) 
BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, BASFI – Bath Ankylosing Spondylitis Functional Index, BASMI 
– Bath Ankylosing Spondylitis Metrology Index, BAS-G – Bath Ankylosing Spondylitis Global Index, ASQoL – Ankylosing 
Spondylitis Quality of Life questionnaire, EQ-VAS – EuroQol Group visual analogue scale,  
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Table 3:  Factors associated with absenteeism score 12 months later 
 
GEE Linear Regression  
(adj. for age, gender and deprivation) 
Baseline factors  Coefficient 95% Confidence Interval 
Work: Job type (labour intensive vs. sedentary) 2.7 (0.4, 4.9)* 
 Presenteeism (%) 0.14 (0.07, 0.2)* 
Clinical: Commencing biologic (yes vs. no) 2.8 (-1.1, 6.7)* 
 Uveitis (yes vs. no) -1.4 (-4.0, 1.1) 
 Psoriasis (yes vs. no) 2.7 (-2.6, 8.0) 
 Inflammatory Bowel Disease (yes vs. no) 1.1 (-4.3, 6.4) 
 Dactylitis (yes vs. no) 3.4 (-6.4, 13.1) 
 Peripheral Joint Involvement (yes vs. no) 3.4 (-0.7, 7.5)* 
 BASDAI (score 0-10) 1.2 (0.7, 1.8)* 
 BASFI (score 0-10) 0.9 (0.4, 1.4)* 
 BASMI (score 0-10) -0.2 (-0.9, 0.4) 
 BAS-G (score 0-10) 1.1 (0.6, 1.6)* 
Patient: ASQoL (score 0-18) 0.5 (0.3, 0.8)* 
 EQ-VAS (score 0-100) -0.1 (-0.2, -0.04)* 
 Activity Impairment (%) 0.13 (0.08, 0.2)* 
 Spinal Pain (score 0-10) 1.01 (0.5, 1.5)* 
 Chalder fatigue (score 0-11) 0.4 (0.02, 0.8)* 
 Sleep Disturbance (score 0-20) 0.4 (0.2, 0.6)* 
 HADS Anxiety (clinical/border vs. none) 2.5 (0.06, 4.9)* 
 HADS Depression (clinical/border vs. none) 3.2 (0.07, 6.4)* 
*eligible for forward stepwise model (p≤0.2) 
BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, BASFI – Bath Ankylosing Spondylitis Functional Index, BASMI 
– Bath Ankylosing Spondylitis Metrology Index, BAS-G – Bath Ankylosing Spondylitis Global Index, ASQoL – Ankylosing 
Spondylitis Quality of Life questionnaire, EQ-VAS – EuroQol Group visual analogue scale,  
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Table 4:  Factors associated with presenteeism score 12 months later 
 
GEE Linear Regression  
(adj. for age, gender and deprivation) 
Baseline predictors  Coefficient 95% Confidence Interval 
Work: Job type (labour intensive vs. sedentary) 7.3 (3.8, 10.7)* 
 Absenteeism (%) 0.2 (0.02, 0.3)* 
Clinical: Commencing biologic (yes vs. no) 6.6 (2.1, 11.1)* 
 Uveitis (yes vs. no) -0.5 (-4.5, 3.6) 
 Psoriasis (yes vs. no) 3.8 (-2.6, 10.2) 
 Inflammatory Bowel Disease (yes vs. no) 1.3 (-3.95, 6.5) 
 Dactylitis (yes vs. no) 6.4 (-4.9, 17.7) 
 Peripheral Joint Involvement (yes vs. no) 6.2 (1.9, 10.6)* 
 BASDAI (score 0-10) 4.2 (3.6, 4.9)* 
 BASFI (score 0-10) 3.7 (3.0, 4.3)* 
 BASMI (score 0-10) 1.4 (0.3, 2.5)* 
 BAS-G (score 0-10) 3.4 (2.8, 4.0)* 
Patient: ASQoL (score 0-18)   2.0 (1.7, 2.3)* 
 EQ-VAS (score 0-100) -0.3 (-0.4, -0.2)* 
 Activity Impairment (%) 0.4 (0.3, 0.43) 
 Spinal Pain (score 0-10) 2.8 (2.2, 3.4)* 
 Chalder fatigue (score 0-11) 2.3 (1.8, 2.8)* 
 Sleep Disturbance (score0-20) 1.1 (0.8, 1.4)* 
 HADS Anxiety (clinical/border vs. none) 10.7 (7.2, 14.2)* 
 HADS Depression (clinical/border vs. none) 10.0 (5.9, 14.1)* 
*eligible for stepwise model 
BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, BASFI – Bath Ankylosing Spondylitis Functional Index, BASMI 
– Bath Ankylosing Spondylitis Metrology Index, BAS-G – Bath Ankylosing Spondylitis Global Index, ASQoL – Ankylosing 
Spondylitis Quality of Life questionnaire, EQ-VAS – EuroQol Group visual analogue scale, 
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Appendix (or web supplementary material) 
 
Table a:  Independent factors associated with absenteeism 12 months later 
 GEE Linear Regression  
Variables in order of model entry: Coefficient 95% Confidence Interval 
Presenteeism (effect per % of presenteeism) 0.12 (0.04, 0.20) 
Profession (labour intensive vs. sedentary) 2.30 (-0.42, 5.03) 
Peripheral Joint Involvement (yes vs. no) 4.31 (-0.42, 5.03) 
Adjusting variables: Age (year) 0.13 (0.005, 0.25) 
Gender (female vs. male) 3.6 (0.45, 6.75) 
Deprivation (increasing quintile) 0.09 (-0.76, 0.94) 
Baseline absenteeism (%) 0.11 (-0.04, 0.25) 
 
 
Table b:  Independent factors associated with presenteeism 12 months later  
 GEE Linear Regression  
Variables in order of model entry: Coefficient 95% Confidence Interval 
BASDAI (score 0-10) 0.76 (-0.23, 1.78) 
Chalder fatigue (score 0-11) 0.65 (0.12, 1.18) 
Profession (labour intensive vs. sedentary) 3.36 (0.61, 6.10) 
BASFI (score 0-10) 0.86 (-0.03, 1.75) 
Adjusting variables: Age (year) -0.001 (-0.12, 0.12) 
Gender (female vs. male) 2.52 (-0.42, 5.47) 
Deprivation (increasing quintile) 0.79 (-0.12, 1.70) 
Baseline presenteeism (%) 0.37 (0.27, 0.47) 
BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, BASFI – Bath Ankylosing Spondylitis Functional Index 
 
 
